BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its Tempus AI price target to $100 from $80 and maintained a Buy rating, citing quarterly results above expectations, raised guidance and a nearly $200 million deal with Bristol Myers Squibb and Pathos. In Q3 2026, revenue rose 23% year over year to $411.5 million, adjusted EPS was $0.07 versus a $0.01 forecast, and adjusted EBITDA turned positive at $25.6 million; full-year revenue guidance increased to $1.60 billion–$1.605 billion. Oncology volume grew more than 30% and minimal residual disease volume rose 300%; shares gained 9% on the earnings day, although InvestingPro analysis flagged possible overvaluation.

Analysis

TEM’s key valuation question is whether data and applications can become repeatable, economically attractive revenue rather than a sequence of bespoke collaborations. That distinction matters more than another analyst target increase: deal announcements can support near-term momentum, but do not establish renewal rates, cash conversion, or durable margins. The BMS collaboration validates demand for Tempus’s data capabilities; the more important second-order effect is whether other drug developers adopt similar external-data workflows, potentially intensifying competition among precision-oncology data providers. BMS may gain access to discovery capabilities, but the disclosed information does not establish a material financial effect for BMY.

Near term, the earnings beat and estimate revisions can sustain momentum, but the six-month share-price advance raises the risk that good execution is already reflected. Over 1–3 months, watch for additional deals converting into reported revenue and for integration progress after Personalis clearance. Over 6–18 months, the thesis depends on repeatable data demand, clinical utility, and the ability to integrate acquired capabilities without diluting operating progress. Risks include deal concentration, slower conversion or renewals, privacy or regulatory constraints, and acquisition execution. The article does not provide deal economics, customer concentration, cash-flow detail, or Personalis transaction terms; verify these before underwriting the upside. A guidance reduction or weakening data-and-applications growth would falsify the near-term momentum case.

Key Decisions for Investors

• TEM: Do not chase the post-results move solely on the higher target. Existing holders can retain exposure, but stage any additions after the next report confirms data-and-applications growth and cash conversion; reassess on a guidance cut or clear segment deceleration.
• Treat further large data deals as catalysts, not yet as proof of recurring economics. Track recognized revenue, renewal evidence, customer concentration, and cash receipts; absent those disclosures, keep position sizing disciplined.
• PSNL: Do not infer standalone upside from regulatory clearance of the acquisition. Verify consideration, closing conditions, and expected integration costs before trading the target or the combined-company thesis.
• BMY: No standalone trade from this collaboration without evidence that it changes earnings, R&D productivity, or capital allocation. The more actionable read-through is competitive validation for oncology-data platforms, not a quantified BMY earnings catalyst.